Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21909908 | 1.00 | MAPT (0.41) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL16674654 | 1.00 | MAPT (0.41) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL19018901 | 1.00 | MAPT (0.41) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| Cadaverine Tartrate SCHEMBL28688232 | 0.90 | MAPT (0.35) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL29592138 | 0.86 | MAPT (0.41) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL19018903 | 0.86 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL16683542 | 0.86 | MAPT (0.44) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL16674652 | 0.83 | MAPT (0.41) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL30278792 | 0.81 | MEN1 (0.45) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL1169394 | 0.81 | MAPT (0.52) | MAPTALDH1A1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115583900-A | Preparation method of high-purity ixaban intermediate | 张邦成都生物医药科技有限公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3395814-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-110028491-B | Fibroblast growth factor receptor inhibitors | 缆图药品公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-108486197-B | Preparation method of high-purity edoxaban intermediate | 爱斯特（成都）生物制药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-107721866-B | Preparation method of edoxaban intermediate | 爱斯特（成都）生物制药股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
| EP-1881988-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006122200-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | MAPT 3420/4885ALDH1A1 897/4885MEN1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.